vs

Side-by-side financial comparison of Lion Group Holding Ltd (LGHL) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Lion Group Holding Ltd is the larger business by last-quarter revenue ($13.3M vs $12.5M, roughly 1.1× Avidity Biosciences, Inc.). Lion Group Holding Ltd runs the higher net margin — -0.4% vs -1398.3%, a 1397.9% gap on every dollar of revenue.

LION is a Canadian electric vehicle manufacturer headquartered in Saint-Jérôme, Quebec. Founded in 2011 as Lion Bus, the company is primarily known for its production of yellow school buses, of which it was the first to mass produce as a fully electric vehicle.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

LGHL vs RNA — Head-to-Head

Bigger by revenue
LGHL
LGHL
1.1× larger
LGHL
$13.3M
$12.5M
RNA
Higher net margin
LGHL
LGHL
1397.9% more per $
LGHL
-0.4%
-1398.3%
RNA

Income Statement — Q2 FY2024 vs Q3 FY2025

Metric
LGHL
LGHL
RNA
RNA
Revenue
$13.3M
$12.5M
Net Profit
$-53.7K
$-174.4M
Gross Margin
Operating Margin
-1513.5%
Net Margin
-0.4%
-1398.3%
Revenue YoY
434.0%
Net Profit YoY
-117.0%
EPS (diluted)
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LGHL
LGHL
RNA
RNA
Q3 25
$12.5M
Q2 25
$3.8M
Q1 25
$1.6M
Q4 24
$3.0M
Q3 24
$2.3M
Q2 24
$13.3M
$2.0M
Q1 24
$3.5M
Q4 23
$2.2M
Net Profit
LGHL
LGHL
RNA
RNA
Q3 25
$-174.4M
Q2 25
$-157.3M
Q1 25
$-115.8M
Q4 24
$-102.3M
Q3 24
$-80.4M
Q2 24
$-53.7K
$-70.8M
Q1 24
$-68.9M
Q4 23
$-60.4M
Operating Margin
LGHL
LGHL
RNA
RNA
Q3 25
-1513.5%
Q2 25
-4448.7%
Q1 25
-8360.9%
Q4 24
-4069.6%
Q3 24
-4200.9%
Q2 24
-4040.4%
Q1 24
-2178.6%
Q4 23
-3043.5%
Net Margin
LGHL
LGHL
RNA
RNA
Q3 25
-1398.3%
Q2 25
-4089.3%
Q1 25
-7360.0%
Q4 24
-3439.5%
Q3 24
-3441.7%
Q2 24
-0.4%
-3461.8%
Q1 24
-1943.4%
Q4 23
-2756.2%
EPS (diluted)
LGHL
LGHL
RNA
RNA
Q3 25
$-1.27
Q2 25
$-1.21
Q1 25
$-0.90
Q4 24
$-0.80
Q3 24
$-0.65
Q2 24
$-0.65
Q1 24
$-0.79
Q4 23
$-0.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LGHL
LGHL
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$29.0M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$28.4M
$1.9B
Total Assets
$74.5M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LGHL
LGHL
RNA
RNA
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$29.0M
$575.8M
Q1 24
$471.4M
Q4 23
$185.1M
Stockholders' Equity
LGHL
LGHL
RNA
RNA
Q3 25
$1.9B
Q2 25
$1.2B
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$1.5B
Q2 24
$28.4M
$1.2B
Q1 24
$830.9M
Q4 23
$500.8M
Total Assets
LGHL
LGHL
RNA
RNA
Q3 25
$2.1B
Q2 25
$1.4B
Q1 25
$1.5B
Q4 24
$1.6B
Q3 24
$1.6B
Q2 24
$74.5M
$1.3B
Q1 24
$951.5M
Q4 23
$628.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LGHL
LGHL
RNA
RNA
Operating Cash FlowLast quarter
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LGHL
LGHL
RNA
RNA
Q3 25
$-156.2M
Q2 25
$-199.7M
Q1 25
$-124.8M
Q4 24
$-99.9M
Q3 24
$-65.6M
Q2 24
$-65.0M
Q1 24
$-70.4M
Q4 23
$16.5M
Free Cash Flow
LGHL
LGHL
RNA
RNA
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
Q4 23
$15.6M
FCF Margin
LGHL
LGHL
RNA
RNA
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Q4 23
713.1%
Capex Intensity
LGHL
LGHL
RNA
RNA
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Q4 23
39.4%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LGHL
LGHL

Trading gains$7.8M59%
Other$2.4M18%
Securities brokerage commissions and fees$1.7M13%
Market making commissions and fees$1.0M8%
Other income$380.2K3%

RNA
RNA

Segment breakdown not available.

Related Comparisons